Limits...
Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.

Shiratsu K, Higuchi K, Nakayama J - Cancer Sci. (2013)

Bottom Line: Loss of αGlcNAc was also significantly associated with poorer patient prognosis in MUC6-positive differentiated-type adenocarcinoma.In undifferentiated-type adenocarcinoma, we observed no significant correlation between mucin phenotypic marker expression, including MUC6, and any clinicopathologic variable.These results together indicate that loss of αGlcNAc in MUC6-positive cancer cells is associated with progression and poor prognosis in differentiated, but not undifferentiated, types of gastric adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan.

Show MeSH

Related in: MedlinePlus

Cancer-specific survival in 113 patients with undifferentiated-type carcinoma based on marker expression: (a) MUC5AC, (b) MUC6, (c) MUC2, and (d) CD10. For each marker, there was no significant difference between survival rates of patients whose tumors were positive or negative for the marker (MUC5AC, P = 0.753; MUC6, P = 0.226; MUC2, P = 0.745; and CD10, P = 0.328).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317868&req=5

fig03: Cancer-specific survival in 113 patients with undifferentiated-type carcinoma based on marker expression: (a) MUC5AC, (b) MUC6, (c) MUC2, and (d) CD10. For each marker, there was no significant difference between survival rates of patients whose tumors were positive or negative for the marker (MUC5AC, P = 0.753; MUC6, P = 0.226; MUC2, P = 0.745; and CD10, P = 0.328).

Mentions: In undifferentiated-type adenocarcinoma, no significant correlations were observed between mucin marker expression and any clinicopathologic variable analyzed (Table2). Mucin marker expression was also not associated with 5-year cancer-specific survival in patients with undifferentiated-type adenocarcinoma (Fig.3).


Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.

Shiratsu K, Higuchi K, Nakayama J - Cancer Sci. (2013)

Cancer-specific survival in 113 patients with undifferentiated-type carcinoma based on marker expression: (a) MUC5AC, (b) MUC6, (c) MUC2, and (d) CD10. For each marker, there was no significant difference between survival rates of patients whose tumors were positive or negative for the marker (MUC5AC, P = 0.753; MUC6, P = 0.226; MUC2, P = 0.745; and CD10, P = 0.328).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317868&req=5

fig03: Cancer-specific survival in 113 patients with undifferentiated-type carcinoma based on marker expression: (a) MUC5AC, (b) MUC6, (c) MUC2, and (d) CD10. For each marker, there was no significant difference between survival rates of patients whose tumors were positive or negative for the marker (MUC5AC, P = 0.753; MUC6, P = 0.226; MUC2, P = 0.745; and CD10, P = 0.328).
Mentions: In undifferentiated-type adenocarcinoma, no significant correlations were observed between mucin marker expression and any clinicopathologic variable analyzed (Table2). Mucin marker expression was also not associated with 5-year cancer-specific survival in patients with undifferentiated-type adenocarcinoma (Fig.3).

Bottom Line: Loss of αGlcNAc was also significantly associated with poorer patient prognosis in MUC6-positive differentiated-type adenocarcinoma.In undifferentiated-type adenocarcinoma, we observed no significant correlation between mucin phenotypic marker expression, including MUC6, and any clinicopathologic variable.These results together indicate that loss of αGlcNAc in MUC6-positive cancer cells is associated with progression and poor prognosis in differentiated, but not undifferentiated, types of gastric adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan.

Show MeSH
Related in: MedlinePlus